These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

382 related items for PubMed ID: 21795364

  • 1. Patient-specific radiation dosimetry of 99mTc-HYNIC-Tyr3-octreotide in neuroendocrine tumors.
    Grimes J, Celler A, Birkenfeld B, Shcherbinin S, Listewnik MH, Piwowarska-Bilska H, Mikolajczak R, Zorga P.
    J Nucl Med; 2011 Sep; 52(9):1474-81. PubMed ID: 21795364
    [Abstract] [Full Text] [Related]

  • 2. Biokinetics and dosimetry in patients of 99mTc-EDDA/HYNIC-Tyr3-octreotide prepared from lyophilized kits.
    González-Vázquez A, Ferro-Flores G, Arteaga de Murphy C, Gutiérrez-García Z.
    Appl Radiat Isot; 2006 Jul; 64(7):792-7. PubMed ID: 16542847
    [Abstract] [Full Text] [Related]

  • 3. Initial direct comparison of 99mTc-TOC and 99mTc-TATE in identifying sites of disease in patients with proven GEP NETs.
    Cwikla JB, Mikolajczak R, Pawlak D, Buscombe JR, Nasierowska-Guttmejer A, Bator A, Maecke HR, Walecki J.
    J Nucl Med; 2008 Jul; 49(7):1060-5. PubMed ID: 18552141
    [Abstract] [Full Text] [Related]

  • 4. Patient-specific dosimetry of 99mTc-HYNIC-Tyr3-Octreotide in children.
    Hou X, Birkenfeld B, Piwowarska-Bilska H, Celler A.
    EJNMMI Phys; 2017 Oct 13; 4(1):24. PubMed ID: 29030760
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
    Storch D, Béhé M, Walter MA, Chen J, Powell P, Mikolajczak R, Mäcke HR.
    J Nucl Med; 2005 Sep 13; 46(9):1561-9. PubMed ID: 16157541
    [Abstract] [Full Text] [Related]

  • 6. Improved kit formulation for preparation of (99m)Tc-HYNIC-TOC: results of preliminary clinical evaluation in imaging patients with neuroendocrine tumors.
    Korde A, Mallia M, Shinto A, Sarma HD, Samuel G, Banerjee S.
    Cancer Biother Radiopharm; 2014 Nov 13; 29(9):387-94. PubMed ID: 25379612
    [Abstract] [Full Text] [Related]

  • 7. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors.
    Gabriel M, Decristoforo C, Donnemiller E, Ulmer H, Watfah Rychlinski C, Mather SJ, Moncayo R.
    J Nucl Med; 2003 May 13; 44(5):708-16. PubMed ID: 12732671
    [Abstract] [Full Text] [Related]

  • 8. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide.
    Bangard M, Béhé M, Guhlke S, Otte R, Bender H, Maecke HR, Biersack HJ.
    Eur J Nucl Med; 2000 Jun 13; 27(6):628-37. PubMed ID: 10901448
    [Abstract] [Full Text] [Related]

  • 9. Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c(RGDfK)]2 for breast cancer imaging.
    Ortiz-Arzate Z, Santos-Cuevas CL, Ocampo-García BE, Ferro-Flores G, García-Becerra R, Estrada G, Gómez-Argumosa E, Izquierdo-Sánchez V.
    Nucl Med Commun; 2014 Apr 13; 35(4):423-32. PubMed ID: 24335877
    [Abstract] [Full Text] [Related]

  • 10. Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT.
    Madrzak D, Mikołajczak R, Kamiński G.
    Nucl Med Rev Cent East Eur; 2016 Apr 13; 19(2):88-92. PubMed ID: 27479886
    [Abstract] [Full Text] [Related]

  • 11. Incremental value of 99mTc-HYNIC-TOC SPECT/CT over whole-body planar scintigraphy and SPECT in patients with neuroendocrine tumours.
    Trogrlic M, Težak S.
    Nuklearmedizin; 2017 Jun 12; 56(3):97-107. PubMed ID: 28164207
    [Abstract] [Full Text] [Related]

  • 12. Clinical indications to the use of (99m)Tc-EDDA/HYNIC-TOC to detect somatostatin receptor-positive neuroendocrine tumors.
    Parisella MG, Chianelli M, D'Alessandria C, Todino V, Mikolajczak R, Papini E, Dierckx RA, Scopinaro F, Signore A.
    Q J Nucl Med Mol Imaging; 2012 Feb 12; 56(1):90-8. PubMed ID: 21068709
    [Abstract] [Full Text] [Related]

  • 13. 99mTc-EDDA/HYNIC-TOC in management of patients with head and neck somatostatin receptor positive tumors.
    Trogrlic M, Tezak S.
    Nucl Med Rev Cent East Eur; 2016 Feb 12; 19(2):74-80. PubMed ID: 27479884
    [Abstract] [Full Text] [Related]

  • 14. [Preliminary clinical application of 99Tcm-HYNIC-TOC imaging in somatostatin receptor-positive tumors].
    Li F, Chen LB, Jing HL, Du YR, Chen F.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Oct 12; 25(5):563-6. PubMed ID: 14650159
    [Abstract] [Full Text] [Related]

  • 15. 99mTc-HYNIC-TOC imaging in the evaluation of pancreatic masses which are potential neuroendocrine tumors.
    Qiao Z, Zhang J, Jin X, Huo L, Zhu Z, Xing H, Li F.
    Clin Nucl Med; 2015 May 12; 40(5):397-400. PubMed ID: 25706799
    [Abstract] [Full Text] [Related]

  • 16. Comparative biodistribution and radiation dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in patients with neuroendocrine tumors.
    Sandström M, Velikyan I, Garske-Román U, Sörensen J, Eriksson B, Granberg D, Lundqvist H, Sundin A, Lubberink M.
    J Nucl Med; 2013 Oct 12; 54(10):1755-9. PubMed ID: 23929824
    [Abstract] [Full Text] [Related]

  • 17. Studies on batch formulation of a freeze dried kit for the preparation of 99mTc-HYNIC-TATE for imaging neuroendocrine tumors.
    Mukherjee A, Korde A, Shinto A, Sarma HD, Kamaleswaran K, Dash A.
    Appl Radiat Isot; 2019 Mar 12; 145():180-186. PubMed ID: 30639635
    [Abstract] [Full Text] [Related]

  • 18. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial.
    Etchebehere EC, de Oliveira Santos A, Gumz B, Vicente A, Hoff PG, Corradi G, Ichiki WA, de Almeida Filho JG, Cantoni S, Camargo EE, Costa FP.
    J Nucl Med; 2014 Oct 12; 55(10):1598-604. PubMed ID: 25168627
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Safety, biodistribution, and dosimetry of 99mTc-HYNIC-annexin V, a novel human recombinant annexin V for human application.
    Kemerink GJ, Liu X, Kieffer D, Ceyssens S, Mortelmans L, Verbruggen AM, Steinmetz ND, Vanderheyden JL, Green AM, Verbeke K.
    J Nucl Med; 2003 Jun 12; 44(6):947-52. PubMed ID: 12791824
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.